Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Neurogene Inc.

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Oversubscribed $200 Million Private Placement
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene to Participate in BMO Genetic Medicines Summit
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Addition to Russell 3000® Index
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene to Participate in Upcoming Investor Conferences
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Business Update and 2024 Outlook
From Neurogene Inc.
Via Business Wire
Tickers NGNE
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
From Neurogene Inc.
Via Business Wire
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces New Development Program in Rett Syndrome Utilizing Novel EXACT Technology Platform
From Neurogene Inc.
Via Business Wire
Neurogene Announces FDA Clearance of IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease
From Neurogene Inc.
Via Business Wire
Neurogene Announces EMA Grants Orphan Drug Designation to CLN5 Batten Disease Gene Therapy
From Neurogene Inc.
Via Business Wire
Neurogene’s AAV Biodistribution Study Shows Route of Administration Essential Component in Optimizing Gene Therapy Treatment for Neurological Disease
From Neurogene Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.